Published online Jul 6, 2021. doi: 10.12998/wjcc.v9.i19.5135
Peer-review started: November 8, 2020
First decision: December 21, 2020
Revised: January 1, 2021
Accepted: May 20, 2021
Article in press: May 20, 2021
Published online: July 6, 2021
Processing time: 220 Days and 4.2 Hours
Core Tip: Documented by accumulated data from coronaviruses studies and considering six identified pitfalls to which most of the studies fall victim, the early antiviral treatment is crucial for reducing viral load, transmission, and preventing disease severity. In coronavirus disease 2019, initiation of interferon-β plus ribavirin plus lopinavir/ritonavir is beneficial when targeting selected patients early during Stage I, and is a regimen that can be administered while the patient is at home in quarantine. If disease progresses to Stages IIb-III, corticosteroids (mainly pulsed methylprednisolone) are effective, but if they fail or extrapulmonary systemic hyperinflammation syndrome develops, tocilizumab (or anakinra) should be co-administered.
